Technical Analysis for BNOEF - Bionomics Ltd

Grade Last Price % Change Price Change
grade D 0.049 4.26% 0.0020
BNOEF closed up 4.26 percent on Wednesday, February 5, 2020, on 8 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical BNOEF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 4.26%
Wide Bands Range Expansion 4.26%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Older signals for BNOEF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Medicine Cancer Biopharmaceutical Treatment Of Cancer Pharmacology Stem Cells Drug Discovery Monoclonal Antibodies Alzheimer's Disease Genomics Central Nervous System Disorders Tumors Cancer Treatment Medical Research Contract Research Services Anxiolytics Merck & Co. Cognitive Impairment Post Traumatic Stress Disorder Treatment Of Central Nervous System Disorders

Is BNOEF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.51
52 Week Low 0.0105
Average Volume 13,000
200-Day Moving Average 0.1621
50-Day Moving Average 0.0548
20-Day Moving Average 0.0557
10-Day Moving Average 0.0487
Average True Range 0.0087
ADX 17.71
+DI 32.4082
-DI 47.7551
Chandelier Exit (Long, 3 ATRs ) 0.0659
Chandelier Exit (Short, 3 ATRs ) 0.0581
Upper Bollinger Band 0.0792
Lower Bollinger Band 0.0322
Percent B (%b) 0.36
BandWidth 84.3806
MACD Line -0.0030
MACD Signal Line -0.0022
MACD Histogram -0.0008
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0490
Resistance 3 (R3) 0.0490 0.0490 0.0490
Resistance 2 (R2) 0.0490 0.0490 0.0490 0.0490
Resistance 1 (R1) 0.0490 0.0490 0.0490 0.0490 0.0490
Pivot Point 0.0490 0.0490 0.0490 0.0490 0.0490
Support 1 (S1) 0.0490 0.0490 0.0490 0.0490 0.0490
Support 2 (S2) 0.0490 0.0490 0.0490 0.0490
Support 3 (S3) 0.0490 0.0490 0.0490
Support 4 (S4) 0.0490